Literature DB >> 8762729

Decreased plasma and extracellular volume in growth hormone deficient adults and the acute and prolonged effects of GH administration: a controlled experimental study.

J Møller1, E Frandsen, S Fisker, J O Jørgensen, J S Christiansen.   

Abstract

OBJECTIVE: There are few data on the endocrine mechanisms underlying the body fluid changes in GH deficiency and their subsequent alteration following GH replacement. We have therefore investigated the time effects of GH on body fluid distribution and fluid regulating hormones in GH deficient adults.
DESIGN: The patients underwent in random order four study periods: (1) saline, a 42-hour infusion following 3 weeks without GH, (2) acute GH, a 42-hour GH infusion following 3 weeks without GH, (3) 3 days GH, a 42-hour GH infusion preceded by 3 weeks without GH and 3 days pretreatment with subcutaneous GH injections, (4) 3 weeks GH, a 42-hour GH infusion after at least 3 weeks GH therapy.
SUBJECTS: Seven GH deficient adult males and 8 healthy control subjects. MEASUREMENTS: During each infusion period 24-hour blood pressure was recorded, bioimpedance was repeatedly measured and blood samples were obtained every 6 hours. After 41 hours extracellular and plasma volumes were determined isotopically. Extracellular volume, plasma volume and bioimpedance were measured in the control group.
RESULTS: GH increased extracellular volume (saline 16.45 +/- 0.79 vs acute GH 16.83 +/- 0.87; vs 3 days GH 17.58 +/- 0.71; vs 3 weeks GH 17.92 +/- 0.88 l, P = 0.01). After 3 weeks of GH, extracellular volumes in the patients and in the control group were identical (control 17.94 +/- 0.32). Plasma volume was increased only after 3 weeks GH treatment (saline 2.93 +/- 0.16 vs acute GH 3.04 +/- 0.22; vs 3 days GH 3.06 +/- 0.07; vs 3 weeks GH 3.37 +/- 0.18 l, P = 0.03), and was decreased compared to the control group (control 3.56 +/- 0.03 l, P < 0.01). Bioimpedance decreased significantly in all treatment periods and was significantly increased compared to the control group. Plasma renin increased during GH administration (saline 16.2 +/- 1.9 vs acute 19.0 +/- 1.9; vs 3 days GH 30.8 +/- 3.0; vs 3 weeks GH 27.0 +/- 3.0 mU/l, P = 0.03), whereas aldosterone and atrial natriuretic factor (ANF) levels remained unaffected by GH. GH caused an increase in systolic blood pressure (BP) and heart rate, whereas diastolic BP remained unaffected.
CONCLUSIONS: The present data show that GH deficiency is associated with decreased plasma volume and extracellular volume. GH exposure acutely increases extracellular volume, whereas substitution for a longer time was required to normalize both extracellular and plasma volumes. Renin seems to be involved in these fluid volume regulating effects of GH.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762729     DOI: 10.1046/j.1365-2265.1996.728550.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Preparation and characterization of poly(D,L-lactide-co-glycolide) microspheres for controlled release of human growth hormone.

Authors:  Yilmaz Capan; Ge Jiang; Stefano Giovagnoli; Kyu-Heum Na; Patrick P DeLuca
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

Review 3.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

4.  Novel serum protein biomarkers indicative of growth hormone doping in healthy human subjects.

Authors:  Juan Ding; Shigeru Okada; Jens Otto Lunde Jørgensen; John J Kopchick
Journal:  Proteomics       Date:  2011-07-27       Impact factor: 3.984

Review 5.  The enigmatic role of growth hormone in age-related diseases, cognition, and longevity.

Authors:  Gabriela Colon; Tatiana Saccon; Augusto Schneider; Marcelo B Cavalcante; Derek M Huffman; Darlene Berryman; Ed List; Yuji Ikeno; Nicolas Musi; Andrzej Bartke; John Kopchick; James L Kirkland; Tamara Tchkonia; Michal M Masternak
Journal:  Geroscience       Date:  2019-09-04       Impact factor: 7.713

6.  Differential effects of growth hormone versus insulin-like growth factor-I on the mouse plasma proteome.

Authors:  Juan Ding; Edward O List; Brian D Bower; John J Kopchick
Journal:  Endocrinology       Date:  2011-07-26       Impact factor: 4.736

7.  Severe hypernatraemia associated with growth hormone replacement therapy in a patient with septo-optic dysplasia.

Authors:  Shivani Misra; Linda Brown Johnston; William Martyn Drake
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 8.  Effects of GH and insulin-like growth factor-I on body composition.

Authors:  J Svensson; L Lönn; G Johannsson; B A Bengtsson
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

9.  Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD).

Authors:  A I Pincelli; R Bragato; M Scacchi; G Branzi; G Osculati; R Viarengo; G Leonetti; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2003-05       Impact factor: 4.256

Review 10.  Pathogenesis and prevalence of hypertension in acromegaly.

Authors:  M Bondanelli; M R Ambrosio; E C degli Uberti
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.